Why the study?
Does rivaroxaban prevent stroke and systemic embolism with acceptable bleeding risk in real-life patients with non-valvular atrial fibrillation?
Does rivaroxaban prevent stroke and systemic embolism with acceptable bleeding risk in real-life patients with non-valvular atrial fibrillation?
Real-world evidence confirms the efficacy and safety of rivaroxaban for stroke prevention in non-valvular atrial fibrillation, consistent with the ROCKET-AF trial.
Supports rivaroxaban consideration for elective AF procedures; confirms ROCKET-AF consistency yet leaves open randomized validation.
Rivaroxaban is a once-daily oral anticoagulant currently marketed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. This indication is largely based on the results of the ROCKET-AF trial. Although these results are robust, studies performed in clinical practice are necessary to confirm these data in real-life patients. These studies have shown rates of stroke and bleeding similar to that found in ROCKET-AF. As an anticoagulant, attention should be paid to making a correct prescription of rivaroxaban, particularly in fragile patients, to reduce the risk of bleeding. In addition, a number of studies have shown that rivaroxaban is cost-effective in clinical practice. Moreover, rivaroxaban is a good alternative to warfarin in patients undergoing elective cardioversion or atrial fibrillation ablation.
No takes yet. Share an insight, caveat, or question.
Barón‐Esquivias et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: